Literature DB >> 35697974

Patient Medication Preferences for Managing Dry Eye Disease: The Importance of Medication Side Effects.

Semra Ozdemir1,2, Sharon Wan Jie Yeo3, Jia Jia Lee4, Adithya Bhaskar4, Eric Finkelstein4,5,6, Louis Tong3,7,8.   

Abstract

OBJECTIVES: The side effects of dry eye medications can lead to medication non-adherence and, eventually, to poor outcomes. This study aimed to quantify to what extent the side effects of dry eye disease (DED) medications (burning/stinging sensation and blurring) are important to patients compared to medication benefits or costs.
METHODS: Patients diagnosed with DED were recruited at a referral eye center in Singapore (n = 139). This study utilized a Discrete Choice Experiment where patients were presented with 10 choice tasks where they were asked to choose between their current medication (or no medication), and two hypothetical medications that varied based on five attributes: duration of burning/stinging, duration of blurring, time to medication effectiveness, medication frequency, and out-of-pocket cost. The main outcomes were relative attribute importance and predicted uptake.
RESULTS: Latent class logistic regressions found two groups with distinct preferences. For both classes, duration of burning/stinging (Class 1 = 23%, Class 2 = 29%) and cost (Class 1 = 24%, Class 2 = 27%) were the most important attributes while duration of blurring (Class 1 = 15%, Class 2 = 9%) was the least important. The predicted uptake of a medication increased 18 percentage-points when burning/stinging duration decreased from 2 h to a few minutes. The predicted uptake for new medications was lowest for those on medication with well-controlled symptoms and highest for those who were not on medication and could not control their symptoms effectively.
CONCLUSION: This study showed that duration of burning/stinging was an important factor when choosing medications. Incorporating patient preferences in medication decisions can potentially improve patient acceptance of a treatment regimen.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Year:  2022        PMID: 35697974      PMCID: PMC9192251          DOI: 10.1007/s40271-022-00586-8

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.481


  26 in total

1.  Anxiety and depression in patients with dry eye syndrome.

Authors:  Meiyan Li; Lan Gong; Xinghuai Sun; William J Chapin
Journal:  Curr Eye Res       Date:  2011-01       Impact factor: 2.424

2.  Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life.

Authors:  Adam J Paulsen; Karen J Cruickshanks; Mary E Fischer; Guan-Hua Huang; Barbara E K Klein; Ronald Klein; Dayna S Dalton
Journal:  Am J Ophthalmol       Date:  2014-01-02       Impact factor: 5.258

Review 3.  TFOS DEWS II Definition and Classification Report.

Authors:  Jennifer P Craig; Kelly K Nichols; Esen K Akpek; Barbara Caffery; Harminder S Dua; Choun-Ki Joo; Zuguo Liu; J Daniel Nelson; Jason J Nichols; Kazuo Tsubota; Fiona Stapleton
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

Review 4.  TFOS DEWS II Epidemiology Report.

Authors:  Fiona Stapleton; Monica Alves; Vatinee Y Bunya; Isabelle Jalbert; Kaevalin Lekhanont; Florence Malet; Kyung-Sun Na; Debra Schaumberg; Miki Uchino; Jelle Vehof; Eloy Viso; Susan Vitale; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

5.  Prevalence of and risk factors for symptomatic dry eye disease in Singapore.

Authors:  Li Li Tan; Philip Morgan; Zhi Qiang Cai; Robert A Straughan
Journal:  Clin Exp Optom       Date:  2014-09-30       Impact factor: 2.742

6.  Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older.

Authors:  Kimberly F Farrand; Moshe Fridman; Ipek Özer Stillman; Debra A Schaumberg
Journal:  Am J Ophthalmol       Date:  2017-07-10       Impact factor: 5.258

7.  Impact of symptomatic dry eye on vision-related daily activities: the Singapore Malay Eye Study.

Authors:  L Tong; S Waduthantri; T Y Wong; S M Saw; J J Wang; M Rosman; E Lamoureux
Journal:  Eye (Lond)       Date:  2010-05-21       Impact factor: 3.775

Review 8.  Patient-reported symptoms in dry dye disease.

Authors:  Kelly K Nichols
Journal:  Ocul Surf       Date:  2006-07       Impact factor: 5.033

9.  Impact of dry eye syndrome on vision-related quality of life.

Authors:  Biljana Miljanović; Reza Dana; David A Sullivan; Debra A Schaumberg
Journal:  Am J Ophthalmol       Date:  2007-01-02       Impact factor: 5.258

10.  Effect of Regulatory Requirement for Patient-Specific Prescriptions for Off-Label Medications on the Use of Intravitreal Bevacizumab.

Authors:  Steven Holfinger; Alexander G Miller; Llewelyn J Rao; Douglas Y Rowland; Joan H Hornik; David G Miller
Journal:  JAMA Ophthalmol       Date:  2016-01       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.